BostonGene and Unilever have announced a strategic partnership to apply artificial intelligence and multiomics research to support future consumer product innovation. The collaboration, announced from BostonGene’s headquarters in Waltham, Massachusetts, aims to combine advanced biological data analysis with consumer goods research to generate new scientific insights for next-generation products.

The initiative brings together BostonGene’s AI-driven analytical platform with Unilever’s research and development expertise across personal care, beauty, home care and food products.

What is the BostonGene–Unilever collaboration?

The collaboration is a research partnership designed to apply AI and multiomics analysis to consumer product science.

Multiomics refers to the integration of biological data sets such as genomics, transcriptomics and immune system data. By combining these data layers with artificial intelligence, researchers can analyse how biological differences influence human responses to products.

The goal is to generate scientific insights that could guide future product innovation.

At a glance

  • Partnership: BostonGene and Unilever strategic research collaboration

  • Focus: AI and multiomics research for consumer product innovation

  • Technology: BostonGene’s AI foundation model for biological data analysis

  • Industry: Consumer goods and personal care product development

  • Objective: Identify biological insights that can inspire new product concepts

  • Location: Collaboration announced in Waltham, Massachusetts

  • Market reach: Products developed by Unilever are sold in more than 190 countries

Why is Unilever investing in AI-driven research?

Consumer goods companies are increasingly investing in advanced science and data analysis to improve product development.

Artificial intelligence allows researchers to analyse complex biological information more quickly and identify patterns that traditional research methods may miss. These insights can help companies design products that better match consumer needs, performance expectations and individual biological differences.

For global FMCG companies, scientific research is becoming a key driver of product differentiation.

What role does BostonGene play in the partnership?

BostonGene contributes its AI foundation model for biological data analysis, originally developed for research in tumour and immune biology.

The platform integrates multiple biological data types into a single analytical framework. By applying this approach to broader human biology research, the collaboration aims to explore biological factors that influence how individuals respond to consumer products.

The technology enables large-scale analysis of biological data sets that would otherwise be difficult to interpret.

How does this fit into wider FMCG innovation trends?

Across the global consumer goods industry, major companies are increasing investment in data-driven product research.

Advanced analytics, biotechnology and artificial intelligence are increasingly used to improve product formulation, safety, performance and consumer experience. These technologies allow companies to move beyond traditional product testing toward predictive scientific models.

The BostonGene partnership reflects this wider shift toward science-based innovation in the FMCG sector.

What happens next?

Researchers from BostonGene and Unilever will begin applying AI and multiomics analysis to study biological factors that influence how consumers respond to products.

Insights from the research may support future innovation programmes and help guide the development of next-generation products across the US FMCG sector and wider global consumer goods industry, shaping long-term product development strategies at Unilever.

Editor’s Note: Unilever is one of the world’s largest consumer goods companies, supplying beauty, personal care, home care and food products in more than 190 countries. The company reported €50.5 billion in sales in 2025 and employs about 96,000 people globally.